Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Respiratory Medicine Reviews
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 1573-398X
  • E-ISSN: 1875-6387

Abstract

Introduction

Perivascular epithelioid cell tumors (PEComa) are rare mesenchymal neoplasms characterized by perivascular epithelioid cells. Despite their common occurrence in the uterus, gastrointestinal tract, and retroperitoneum, this study presents an exceptional case of PEComa identified in the lung, warranting unique molecular exploration.

Case Report

A 50-year-old man was diagnosed with a 6 cm neoplasm in the lower lobe of the right lung without enlarged lymph nodes during a routine examination. Thoracotomy, extended lower bilobectomy, and D3 lymphadenectomy were performed. Histological and immunohistochemical analysis diagnosed a PEComa. No conventional and mutations specific to PEComa, which resulted in mTOR pathway activation, were detected by whole-exome sequencing. In contrast, mutations were unveiled in the , , and genes that could be an alternative mechanism governing mTOR activation.

Conclusion

These findings provide novel insights into the molecular intricacies of lung PEComa, showcasing the distinctive roles of , , and mutations.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X322092241022090829
2024-10-28
2025-04-13

  • From This Site

    /content/journals/crmr/10.2174/011573398X322092241022090829
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AkumallaS. MadisonR. LinD.I. SchrockA.B. YakirevichE. RosenzweigM. BalarA.V. FramptonG.M. EdgerlyC. ErlichR.L. MillerV.A. GanesanS. RossJ.S. AliS.M. Characterization of clinical cases of malignant PEComa via comprehensive genomic profiling of DNA and RNA.Oncology2020981290591210.1159/00051024132966992
     [Google Scholar]
  2. CzarneckaA.M. SkoczylasJ. BartnikE. ŚwitajT. RutkowskiP. Management strategies for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa): Challenges and solutions.Cancer Manag. Res.20231561562310.2147/CMAR.S35128437440783
     [Google Scholar]
  3. YuS. ZhaiS. GongQ. HuX. YangW. LiuL. KongY. WuL. PuX. Perivascular epithelioid cell tumor of the lung: A case report and literature review.Thorac. Cancer202213172542255310.1111/1759‑7714.1458335871533
     [Google Scholar]
  4. MeredithL. ChaoT. NevlerA. Basu MallickA. SinglaR.K. McCueP.A. BowneW.B. JiangW. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: A case report.Diagn. Pathol.20231814510.1186/s13000‑023‑01323‑x37041531
     [Google Scholar]
  5. McKennaA. HannaM. BanksE. SivachenkoA. CibulskisK. KernytskyA. GarimellaK. AltshulerD. GabrielS. DalyM. DePristoM.A. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data.Genome Res.20102091297130310.1101/gr.107524.11020644199
     [Google Scholar]
  6. WangK. LiM. HakonarsonH. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data.Nucleic Acids Res.20103816e16410.1093/nar/gkq60320601685
     [Google Scholar]
  7. XieZ. BaileyA. KuleshovM.V. ClarkeD.J.B. EvangelistaJ.E. JenkinsS.L. LachmannA. WojciechowiczM.L. KropiwnickiE. JagodnikK.M. JeonM. Ma’ayanA. Gene set knowledge discovery with Enrichr.Curr. Protoc.202113e9010.1002/cpz1.9033780170
     [Google Scholar]
  8. YangS. HuiT.L. WangH.Q. ZhangX. MiY.Z. ChengM. GaoW. GengC.Z. LiS.N. High expression of autophagy-related gene EIF4EBP1 could promote tamoxifen resistance and predict poor prognosis in breast cancer.World J. Clin. Cases202311204788479910.12998/wjcc.v11.i20.478837583983
     [Google Scholar]
  9. PopovaN.V. JückerM. The role of mTOR signaling as a therapeutic target in cancer.Int. J. Mol. Sci.2021224174310.3390/ijms2204174333572326
     [Google Scholar]
  10. HermesN. KewitzS. StaegeM.S. Preferentially expressed antigen in melanoma (PRAME) and the PRAME family of leucine-rich repeat proteins.Curr. Cancer Drug Targets201616540041410.2174/156800961666615122215181826694250
     [Google Scholar]
  11. ChiangS. VasudevarajaV. SerranoJ. StewartC.J.R. OlivaE. Momeni-BoroujeniA. JungbluthA.A. Da Cruz PaulaA. da SilvaE.M. WeigeltB. ParkK.J. SoslowR.A. MuraliR. EllensonL.H. BenayedR. LadanyiM. Abu-RustumN.R. DicksonM.A. CohenS. AghajanianC. HensleyM.L. LeeC.H. SnuderlM. KonnerJ.A. TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition.Mod. Pathol.202235111712710.1038/s41379‑021‑00922‑734561551
     [Google Scholar]
  12. MoschettaM. RealeA. MarascoC. VaccaA. CarratùM.R. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.Br. J. Pharmacol.2014171163801381310.1111/bph.1274924780124
     [Google Scholar]
  13. TianT. LiX. ZhangJ. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy.Int. J. Mol. Sci.201920375510.3390/ijms2003075530754640
     [Google Scholar]
  14. WangZ. FengX. MolinoloA.A. MartinD. Vitale-CrossL. NohataN. AndoM. WahbaA. AmornphimolthamP. WuX. GilardiM. AllevatoM. WuV. SteffenD.J. TofilonP. SonenbergN. CalifanoJ. ChenQ. LippmanS.M. GutkindJ.S. 4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer.Cancer Res.20197971438145010.1158/0008‑5472.CAN‑18‑122030894372
     [Google Scholar]
  15. YangH.Y. XueL.Y. XingL.X. WangJ. WangJ.L. YanX. ZhangX.H. Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma.Mol. Med. Rep.20137253754210.3892/mmr.2012.120823229050
     [Google Scholar]
  16. RutkovskyA.C. YehE.S. GuestS.T. FindlayV.J. Muise-HelmericksR.C. ArmesonK. EthierS.P. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.BMC Cancer201919149110.1186/s12885‑019‑5667‑431122207
     [Google Scholar]
  17. GlutschV. WobserM. SchillingB. GesierichA. GoebelerM. KneitzH. PRAME expression as helpful immunohistochemical marker in rhabdoid melanoma.Dermatopathology (Basel)20229214815710.3390/dermatopathology902001935645230
     [Google Scholar]
  18. CammareriC. BeltzungF. MichalM. VanherseckeL. CoindreJ.M. VelascoV. Le LoarerF. VergierB. PerretR. PRAME immunohistochemistry in soft tissue tumors and mimics: A study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.Virchows Arch.2023483214515610.1007/s00428‑023‑03606‑637477762
     [Google Scholar]
  19. KlineN. MengeT.D. HrycajS.M. AndeaA.A. PatelR.M. HarmsP.W. ChanM.P. BreslerS.C. PRAME expression in challenging dermal melanocytic neoplasms and soft tissue tumors with melanocytic differentiation.Am. J. Dermatopathol.202244640441010.1097/DAD.000000000000212834991102
     [Google Scholar]
  20. SmithgallM.C. Liu-JarinX. ChenX. SinghK. QuddusM.R. CimicA. Diagnostic utility of PRAME immunohistochemistry in PEComa family of tumors and morphologic mimics with emphasis on the gynecologic tract.Hum. Pathol.2023138121710.1016/j.humpath.2023.05.00637209921
     [Google Scholar]
  21. HarrisT. FitzgeraldJ. CoyleA.J. ReissT. SauerK. T cell therapies for cancer.GEN Biotechnol.20221310.1089/genbio.2022.0011
     [Google Scholar]
/content/journals/crmr/10.2174/011573398X322092241022090829
Loading
Novel Driver Genes and Mutations in Lung Pecoma: A Case Report
Current Respiratory Medicine Reviews 21, 281 (2025); https://doi.org/10.2174/011573398X322092241022090829
/content/journals/crmr/10.2174/011573398X322092241022090829
/content/journals/crmr/10.2174/011573398X322092241022090829
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Case Report
Keyword(s): gene; Lung; mutation; pecoma; signaling pathway, molecular intricacies

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test